Financial Performance - The company's revenue for Q3 2021 was ¥178,250,421.11, a decrease of 68.91% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2021 was ¥113,712,536.77, down 72.66% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥98,477,492.32, reflecting a decline of 76.21% compared to the previous year[4]. - Basic and diluted earnings per share for Q3 2021 were both ¥2.0067, a decrease of 75.39% year-on-year[7]. - Total operating revenue for the current period is 812,948,531.27 CNY, a decrease of approximately 24% compared to 1,068,535,711.45 CNY in the previous period[48]. - Net profit for the current period is 556,362,582.99 CNY, down from 750,594,220.68 CNY, reflecting a decrease of around 26%[51]. - The total comprehensive income attributable to the parent company was CNY 557,545,024.32, compared to CNY 752,495,618.77 in the previous period, reflecting a decrease of approximately 26%[54]. - Basic and diluted earnings per share were CNY 10.5195, down from CNY 14.7175 in the previous period, indicating a decline of about 29.8%[54]. Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥6,679,292,731.77, an increase of 355.92% from the end of the previous year[7]. - The company's total assets amounted to RMB 6,679,292,731.77, a significant increase from RMB 1,465,027,156.89 as of December 31, 2020[38]. - Total liabilities decreased to 95,959,539.44 CNY from 166,383,639.22 CNY, a reduction of approximately 42%[44]. - Total liabilities reached 166,383,639.22, down from 189,672,693.69, indicating a reduction of 23,289,054.47[69]. - Owner's equity increased significantly to 6,583,333,192.33 CNY, compared to 1,298,643,517.67 CNY, representing an increase of about 408%[47]. - Owner's equity totaled 1,298,643,517.67, remaining unchanged from the previous period[72]. Cash Flow - The company reported a net cash flow from operating activities of ¥455,852,218.88, down 15.55% year-on-year[4]. - Cash inflow from operating activities totaled CNY 872,847,387.20, an increase from CNY 800,081,034.60 in the previous period, representing a growth of approximately 9%[57]. - Cash outflow from operating activities was CNY 416,995,168.32, compared to CNY 260,311,528.93 in the previous period, showing an increase of about 60%[57]. - Cash inflow from investment activities was CNY 2,545,611,806.61, significantly higher than CNY 292,363,345.33 in the previous period, indicating a substantial increase[60]. - Cash outflow from investment activities totaled CNY 3,123,661,450.28, compared to CNY 742,079,800.52 in the previous period, marking an increase of approximately 320%[60]. - Net cash flow from financing activities was CNY 4,720,050,530.28, a significant improvement from a net outflow of CNY 2,900,000.00 in the previous period[60]. - The cash and cash equivalents at the end of the period amounted to CNY 4,654,977,849.90, compared to CNY 96,907,321.22 in the previous period, showing a substantial increase[60]. - The company reported a net increase in cash and cash equivalents of CNY 4,598,862,076.90, compared to CNY 86,627,000.35 in the previous period, indicating a strong cash position[60]. Investments and Expenses - R&D expenses surged to ¥32,116,971.18, an increase of 84.01%, indicating a significant boost in research and development investments[15]. - Investment income rose dramatically by 1,885.69% to ¥27,071,806.61, attributed to returns from matured financial products[15]. - Financial expenses decreased by 80.93% to ¥2,593,271.97, primarily due to currency exchange rate fluctuations[15]. - The company received government subsidies amounting to ¥1,050,000.00 in the current period[9]. - Other income grew by 196.21% to ¥3,353,594.12, largely from received listing subsidies[15]. Future Plans and Strategies - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[4]. - The company plans to use RMB 114,500.00 million of the excess raised funds to permanently supplement its working capital, as approved in the board and shareholder meetings[29]. - The company intends to use RMB 90,384,095.37 to replace self-raised funds previously invested in projects, including RMB 82,838,085.94 for the biological reagent R&D center and RMB 7,546,009.43 for issuance costs[33]. - The company has approved the use of up to RMB 320,000.00 million of temporarily idle raised funds for cash management, investing in high-security and liquid financial products for a period of 12 months[34]. - The company has signed an agreement to establish a wholly-owned subsidiary in the Taizhou Medical High-tech Industrial Park, enhancing its operational footprint[37]. Audit and Compliance - The company has not audited the third-quarter report, which may affect stakeholder confidence in the reported figures[72]. - The company is expected to continue monitoring its financial position closely in light of the recent adjustments in asset and liability totals[72].
义翘神州(301047) - 2021 Q3 - 季度财报